Candesartan Cilexetil Drug Market to Witness Significant Growth of USD $2.04 Billion with 5.5% CAGR by 2029
Get 20% Off Market Intelligence Reports With Code ONLINE20 – Track Global Tariffs, Economic Shifts, and Sector Transformations
What Is the Growth Potential of the Candesartan Cilexetil Drug Market in the Next Decade?
The candesartan cilexetil drug market size has grown steadily in recent years. It will grow from $1.57 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to increasing prevalence of hypertension, a rising geriatric population, increasing incidence of chronic diseases, increasing focus on preventative care, and growing healthcare expenditure.
The candesartan cilexetil drug market size is expected to see strong growth in the next few years. It will grow to $2.04 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to the expansion of generic drug availability, the rising incidence of lifestyle-related diseases, government initiatives for affordable hypertension care, the increasing prevalence of cardiovascular diseases, and the growing adoption of combination therapies. Major trends in the forecast period include a shift toward generic candesartan formulations, the development of fixed-dose combination drugs, digital health integration for hypertension monitoring, a growing focus on patient compliance, and increasing research on novel delivery mechanisms.
Claim your free report sample now:
What Are the Major Drivers Influencing the Candesartan Cilexetil Drug Market?
The rising prevalence of hypertension is expected to propel the growth of the candesartan cilexetil drug market going forward. Hypertension, also known as high blood pressure, refers to a medical condition where the force of the blood against the walls of the arteries is consistently too high, typically defined as a reading of 130/80 mmHg or higher. The prevalence of hypertension is due to increasingly unhealthy lifestyle factors, such as poor diet, lack of physical activity, and high-stress levels. Candesartan cilexetil drug helps manage hypertension by blocking the action of angiotensin II, a hormone that constricts blood vessels, relaxing the blood vessels and reducing blood pressure. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, from August 2021 to August 2023, hypertension prevalence grew significantly, rising by 124.48% in the transition from the 18–39 age group to the 40–59 age group, and by 36.38% as it moved from the 40–59 age group to individuals aged 60 and older. Therefore, the increasing burden of hypertension is fueling demand for the candesartan cilexetil drug market.
Which Segment Holds the Largest Share in the Candesartan Cilexetil Drug Market?
The candesartan cilexetil drug market covered in this report is segmented –
1) By Product Type: Tablets, Capsules, Other Product Types
2) By Indication: Hypertension, Heart Failure, Diabetic Nephropathy, Left Ventricular Hypertrophy
3) By Dosage Strength: 4 MG, 8 MG, 16 MG, 32 MG
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Healthcare Facilities
5) By Application: Adult, Children And Adolescent
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Dispersible Tablets, Chewable Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gelatin Capsules, Modified-Release Capsules
3) By Other Product Types: Oral Suspensions, Injectable Formulations, Combination Drug Formulations
How Are Innovation and Technology Shaping the Future Trends of the Candesartan Cilexetil Drug Market?
Major companies operating in the candesartan cilexetil drug market are focusing on developing innovative formulations such as treatments for hypertension, combination therapies with other antihypertensive drugs, and extended-release versions to improve patient adherence and enhance therapeutic outcomes. Treatment for hypertension is the use of medications, lifestyle changes, and other interventions aimed at lowering and managing high blood pressure (hypertension) to reduce the risk of complications such as heart disease, stroke, and kidney damage. For instance, in March 2025, Scienture Inc., a US-based pharmaceutical company, received approval from the US Food & Drug Administration (USFDA) for its New Drug Application (NDA) for SCN-102, launched as Arbli, a losartan potassium oral suspension (10 mg/mL). An angiotensin II receptor blocker (ARB) formulation offers an alternative for patients with difficulty swallowing tablets, particularly in pediatric and geriatric populations. The launch reflects the growing interest in alternative dosage forms in the antihypertensive market and underlines the shift toward personalized, patient-friendly drug delivery systems.
Which Major Companies Are Operating in the Candesartan Cilexetil Drug Market?
Major companies operating in the candesartan cilexetil drug market are Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Viatris Inc., Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences Ltd., Hetero Drugs Limited, Torrent Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited, Oubari Pharmaceutical Co.
Get the full candesartan cilexetil drug market report here:
Which Region Is Expected to Lead the Candesartan Cilexetil Drug Market by 2029?
North America was the largest region in the candesartan cilexetil drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candesartan cilexetil drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment